Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Vysis v. Oncor

This article was originally published in The Gray Sheet

Executive Summary

Oncor will not contest during an April hearing in the U.S. District Court of San Francisco that its sequence fluorescence in situ hybridization probes for analysis of chromosome preparations (in metaphase) infringe a University of California patent (No. 5,447,841), rights to which are licensed exclusively by Vysis. Instead, Oncor maintains that the patent is "invalid and unenforceable" and the court will not rule in Vysis' favor. In addition, Oncor "does not concede infringement of Oncor's Inform HER-2/neu gene detection system," which involves analysis of nuclei of whole cells. Vysis, which employs the technology in its fluorescence in situ hybridization (FISH) probes, maintains that Oncor concedes in a recent letter to the court that its products contain repetitive sequences of DNA, "a concession that will make it far easier for Vysis to prove use of the products infringes the patent"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel